# Once-Weekly IcoSema for Type 2 Diabetes: What COMBINE 4 Found > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/icosema-combine-4-type-2-diabetes-trial/ > **Published:** 2026-08-15T10:25:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T22:00:31-04:00 > **Clinical Summary:** IcoSema COMBINE 4 trial: Once-weekly IcoSema lowered HbA1c and produced a more favorable body-weight change than daily insulin glargine over 40 weeks. Clin --- CED Clinical Relevance #90 [Clinical Evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) Update A peer-reviewed, multicenter, randomized phase 3b trial compared a once-weekly fixed combination of insulin icodec and semaglutide with once-daily insulin glargine in 485 adults. Clinical Insight | CED Clinic In a 40-week randomized phase 3b trial, once-weekly IcoSema produced a larger HbA1c reduction and more favorable body-weight change than once-daily insulin glargine U100 in insulin-naive adults with type 2 diabetes inadequately controlled on oral medicines. Clinically significant or severe hypoglycemia occurred less often with IcoSema, while gastrointestinal disorders were its most frequent [adverse events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/). Because the trial was open-label, treat-to-target, and funded by Novo Nordisk, it supports a product-specific efficacy and safety signal rather than a class-wide claim, an approval claim, or proof of long-term cardiovascular benefit. GLP-1IcoSemaType 2 DiabetesPhase 3b[Randomized Trial](https://cedclinic.com/cannabis-cannabinoids-therapeutic-applications-review/) Audience Adults with type 2 diabetes considering injectable treatment, families, primary-care clinicians, endocrinology clinicians, and readers following GLP-1 research Primary Topic IcoSema and type 2 diabetes Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42594928/) A 485-person randomized phase 3b trial found that once-weekly IcoSema lowered HbA1c and body weight more than once-daily insulin glargine, with fewer clinically significant or severe hypoglycemia episodes. The open-label, sponsor-funded trial does not establish long-term cardiovascular benefit, comparative value against separate modern GLP-1 regimens, or current approval. What This Study Teaches Us Among 485 randomized participants, mean HbA1c changed by -3.32 percentage points with once-weekly IcoSema and -2.44 points with daily glargine at week 40. Mean body weight changed by -0.79 kg with IcoSema and +3.81 kg with glargine, while the rate of clinically significant or severe hypoglycemia was 0.29 versus 0.59 episodes per person-year. Why This Matters People beginning insulin often balance glycemic control, weight change, hypoglycemia, treatment burden, and gastrointestinal tolerability. COMBINE 4 directly tested those tradeoffs, but the investigational fixed-ratio combination should not be treated as interchangeable with semaglutide alone, insulin alone, or other diabetes regimens. Study Snapshot Study Type Open-label, multicenter, treat-to-target, randomized phase 3b trial Population 485 insulin-naive adults with type 2 diabetes inadequately controlled on oral glucose-lowering medicines Setting 97 sites across nine countries Intervention Once-weekly subcutaneous IcoSema, a fixed combination of insulin icodec and semaglutide Comparator Once-daily subcutaneous insulin glargine U100 Duration 40 weeks, with [adverse events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/) recorded through week 45 Primary Outcome Change in HbA1c from baseline to week 40 Primary Result -3.32 percentage points with IcoSema versus -2.44 with glargine; estimated treatment difference -0.88 points, 95% CI -1.12 to -0.63 Body-Weight Result -0.79 kg with IcoSema versus +3.81 kg with glargine; estimated treatment difference -4.61 kg, 95% CI -5.46 to -3.75 Hypoglycemia Result 0.29 versus 0.59 clinically significant or severe episodes per person-year; rate ratio 0.56, 95% CI 0.32 to 0.97 [Adverse Events](https://cedclinic.com/cbd-endocrine-effects-gynecomastia-risk-safety/) Gastrointestinal disorders were most frequent with IcoSema Journal The Lancet Diabetes & Endocrinology Published August 13, 2026 PMID / DOI 42594928 / 10.1016/S2213-8587(26)00136-1 Major Limitation Open-label design, 40-week duration, treat-to-target protocol, investigational product, and Novo Nordisk funding Clinical Bottom Line Once-weekly IcoSema outperformed daily insulin glargine for HbA1c and body-weight change over 40 weeks and had a lower rate of clinically significant or severe hypoglycemia in this trial. The result is clinically important, but it does not settle long-term outcomes, cost, access, adherence, or comparisons with other modern diabetes strategies. HbA1c Favored IcoSema Mean HbA1c fell by 3.32 percentage points with IcoSema and 2.44 points with glargine at week 40. The between-group estimate favored IcoSema by 0.88 percentage points, but the treat-to-target design and open-label treatment should remain part of the interpretation. Weight Moved in Opposite Directions Mean body weight decreased by 0.79 kg with IcoSema and increased by 3.81 kg with glargine. This reflects the tested fixed combination. It should not be used to infer how every insulin and GLP-1 pairing will perform. Hypoglycemia Was Less Frequent The rate of clinically significant or severe hypoglycemia was 0.29 episodes per person-year with IcoSema and 0.59 with glargine. The confidence interval for the rate ratio was 0.32 to 0.97, so the result favored IcoSema but remained less precise than the HbA1c estimate. Gastrointestinal Events Matter Gastrointestinal disorders were the most frequently reported adverse events with IcoSema, consistent with semaglutide exposure. The abstract does not provide every event count or discontinuation detail, so tolerability should not be reduced to the hypoglycemia result alone. IcoSema Remains Product-Specific IcoSema combines once-weekly insulin icodec with semaglutide in a fixed formulation and was investigational in the trial record. The study does not establish approval in every jurisdiction, affordability, real-world adherence, cardiovascular-event reduction, or superiority to separately titrated components. How Strong Is This Evidence? Randomization, 485 participants, 97 sites in nine countries, a prespecified HbA1c endpoint, an active insulin comparator, and concordant HbA1c, weight, and hypoglycemia findings support a strong 40-week product-specific signal. Where This Paper Deserves Skepticism The trial was open-label, used treat-to-target titration, lasted 40 weeks, evaluated an investigational fixed-ratio product, and was funded by Novo Nordisk. The abstract reports gastrointestinal disorders as most frequent with IcoSema but does not provide full event-level detail. What This Paper Does Not Show COMBINE 4 does not establish cardiovascular-event or mortality benefit, long-term durability beyond 40 weeks, outcomes after discontinuation, superiority to separate insulin plus semaglutide titration, affordability, real-world adherence, or suitability for every person with type 2 diabetes. It also does not show that IcoSema is approved or available in every jurisdiction. How This Fits With the Broader Clinical Conversation Fixed-ratio insulin and GLP-1 combinations aim to simplify treatment while balancing glycemic control, weight, and hypoglycemia. A weekly formulation may reduce injection frequency, but convenience, persistence, access, and cost require direct real-world measurement. For patients, the relevant comparison is not simply weekly versus daily. Baseline HbA1c, hypoglycemia risk, gastrointestinal tolerance, kidney and cardiovascular disease, medication access, and the ability to titrate each component all influence clinical fit. Dr. Caplan’s Take *I read COMBINE 4 as a strong randomized signal that this specific weekly combination can improve glucose control while avoiding the weight gain often seen with basal insulin initiation. That is useful, but it is not the same as proving that one fixed combination is best for every patient.* *The patient-level question remains whether the formulation’s dosing, titration, adverse effects, approval status, access, and long-term evidence fit the individual better than established alternatives.* What a Careful Reader Should Take Away A careful reader should conclude that IcoSema produced better 40-week HbA1c and weight outcomes than glargine U100, with fewer clinically significant or severe hypoglycemia episodes, while recognizing that long-term outcomes, approval, access, and broader [comparative effectiveness](https://cedclinic.com/psychedelic-therapies-for-depression-efficacy-debate/) remain unresolved. Evidence Interpretation Guide Table of Contents - [How to Read a Positive Open-Label Diabetes Trial](#How_to_Read_a_Positive_Open-Label_Diabetes_Trial)[Four distinctions that matter](#Four_distinctions_that_matter) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[A Weekly Option Is Not Automatically the Right Option](#A_Weekly_Option_Is_Not_Automatically_the_Right_Option) - [Concordant Efficacy and Safety Signals](#Concordant_Efficacy_and_Safety_Signals) - [Open-Label and Sponsor-Funded](#Open-Label_and_Sponsor-Funded) - [Forty Weeks Is Not Long-Term Outcomes Evidence](#Forty_Weeks_Is_Not_Long-Term_Outcomes_Evidence) - [A New Comparison in the IcoSema Program](#A_New_Comparison_in_the_IcoSema_Program) - [Injection Frequency Is Only One Burden](#Injection_Frequency_Is_Only_One_Burden) - [Durability and Real-World Use Come Next](#Durability_and_Real-World_Use_Come_Next) - [Approval and Coverage Must Be Named Precisely](#Approval_and_Coverage_Must_Be_Named_Precisely) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Read a Positive Open-Label Diabetes Trial The randomized active-comparator result is clinically meaningful. Its reach is limited by duration, treatment structure, product status, and sponsor involvement. ### Four distinctions that matter **Glycemic efficacy versus long-term outcomes**A 40-week HbA1c benefit does not establish cardiovascular-event reduction, mortality benefit, or durability over years. **Fixed combination versus separate components**The trial tested IcoSema as one product, not every way of combining basal insulin and semaglutide. **Randomized versus blinded**Randomization reduces allocation bias, while open-label treatment can still influence behavior, reporting, and treatment management. **Trial result versus availability**Peer-reviewed phase 3b evidence does not by itself establish regulatory approval, coverage, or access in a given jurisdiction. The Research Question Can once-weekly IcoSema improve HbA1c and body-weight outcomes compared with once-daily insulin glargine in insulin-naive adults with inadequately controlled type 2 diabetes? The Patient Question Does this mean a weekly fixed combination is available and better for me than my current options? The Bottom Line The trial supports a strong product-specific efficacy signal, while clinical decisions still require approved-product information and individual assessment. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview Eight perspectives separate the randomized efficacy signal from unanswered questions about open-label treatment, tolerability, approval, access, durability, and individual fit. #### A Weekly Option Is Not Automatically the Right Option The trial suggests fewer injections and favorable average glucose and weight outcomes with IcoSema. Personal fit still depends on approval, access, gastrointestinal tolerance, hypoglycemia risk, and treatment goals. Lens takeaway Do not change insulin or GLP-1 treatment without clinical supervision. #### Concordant Efficacy and Safety Signals HbA1c, body weight, and hypoglycemia all favored IcoSema in the randomized comparison. The fixed-ratio format limits separate titration of its insulin and semaglutide components. Lens takeaway Keep interpretation product-specific and patient-specific. #### Open-Label and Sponsor-Funded Open-label treatment can affect reporting and management even when endpoints include laboratory measures. Novo Nordisk funding makes full reporting and independent confirmation particularly important. Lens takeaway Disclosure should sharpen scrutiny, not erase the randomized result. #### Forty Weeks Is Not Long-Term Outcomes Evidence The study was long enough to measure HbA1c and weight but not cardiovascular events or multi-year durability. Adverse-event interpretation also needs full event and discontinuation data. Lens takeaway Do not extend surrogate outcomes beyond the trial. #### A New Comparison in the IcoSema Program Earlier COMBINE trials compared IcoSema with other insulin strategies. COMBINE 4 specifically addresses insulin-naive adults starting injectable intensification against daily glargine. Lens takeaway Population and comparator define what this trial adds. #### Injection Frequency Is Only One Burden Weekly dosing may be attractive, but affordability, storage, titration, nausea, coverage, and follow-up also shape persistence. The trial did not establish real-world adherence or cost-effectiveness. Lens takeaway Convenience claims need direct measurement. #### Durability and Real-World Use Come Next Longer follow-up should assess persistence, cardiovascular and kidney outcomes, uncommon harms, and outcomes after discontinuation. Comparisons with separately titrated modern regimens would clarify flexibility and value. Lens takeaway Phase 3b efficacy is an important step, not the final evidence layer. #### Approval and Coverage Must Be Named Precisely Publication does not establish that IcoSema is approved, covered, or available in every jurisdiction. Public communication should separate development evidence from current prescribing status. Lens takeaway Precise status language protects patients from premature claims. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Once-Weekly+IcoSema+for+Type+2+Diabetes%3A+What+COMBINE+4+Found&url=https%3A%2F%2Fcedclinic.com%2Ficosema-combine-4-type-2-diabetes-trial%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Ficosema-combine-4-type-2-diabetes-trial%2F) [BlueSky](https://bsky.app/intent/compose?text=Once-Weekly+IcoSema+for+Type+2+Diabetes%3A+What+COMBINE+4+Found%20https%3A%2F%2Fcedclinic.com%2Ficosema-combine-4-type-2-diabetes-trial%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial](https://pubmed.ncbi.nlm.nih.gov/42594928/) Related Reading at CED Clinic Continue exploring the evidence [GLP-1 Drugs Explained: Clinical Evidence and Options](https://cedclinic.com/glp-1-drugs-clinical-evidence-options-2026/) A patient-facing overview of GLP-1 therapy, evidence, and practical treatment distinctions. [Review the GLP-1 overview](https://cedclinic.com/glp-1-drugs-clinical-evidence-options-2026/) [Comparing Tirzepatide and Semaglutide for Weight Loss](https://cedclinic.com/tirzepatide-weight-loss-comparison-efficacy-safety/) Related context on established incretin therapies and why cross-trial comparisons require caution. [Compare established treatment evidence](https://cedclinic.com/tirzepatide-weight-loss-comparison-efficacy-safety/) [GLP-1 Receptor Agonists: Safety and Clinical Evidence](https://cedclinic.com/glp-1-receptor-agonists-safety-profile-review/) A broader review of GLP-1 safety questions, clinical outcomes, and [patient counseling](https://cedclinic.com/stroke-risk-assessment-substance-use/). [Read the safety review](https://cedclinic.com/glp-1-receptor-agonists-safety-profile-review/) Similar Studies on CEDClinic.com Earlier coverage on closely related evidence When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved. Related digest item [Tirzepatide vs Semaglutide: Key Clinical Evidence](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) The Foundayo clinical trial provides important data on GLP-1 therapy for type 2 diabetes patients with cardiovascular risk. This trial compares Foundayo against insulin glargine, highlighting efficacy and safety. Clinic… Covers a closely related topic; this CED post is older by about 118 days and gives earlier context. [Compare earlier coverage](https://cedclinic.com/glp-1-cannabis-use-disorder-bmj-cohort-study/) ## Frequently Asked Questions What did COMBINE 4 test? It compared once-weekly IcoSema with once-daily insulin glargine U100 for 40 weeks in 485 insulin-naive adults with type 2 diabetes inadequately controlled on oral medicines. What is IcoSema? IcoSema is a fixed-ratio combination of once-weekly insulin icodec and the GLP-1 analogue semaglutide. How did HbA1c change? Mean HbA1c fell by 3.32 percentage points with IcoSema and 2.44 points with glargine at week 40. How did body weight change? Mean body weight decreased by 0.79 kg with IcoSema and increased by 3.81 kg with glargine. What happened with hypoglycemia? Clinically significant or severe hypoglycemia occurred at 0.29 episodes per person-year with IcoSema and 0.59 with glargine. What adverse events were most common? The abstract reports gastrointestinal disorders as the most frequently reported adverse events with IcoSema. Was the trial blinded? No. It was randomized but open-label, so participants and investigators knew the assigned treatment. Does the trial prove cardiovascular benefit? No. COMBINE 4 measured glycemic, body-weight, and safety outcomes, not cardiovascular-event or mortality benefit. Is IcoSema approved everywhere? No conclusion about universal approval or availability follows from this publication. Regulatory and prescribing status must be checked by jurisdiction. What is the practical takeaway? IcoSema showed a strong 40-week product-specific signal compared with glargine, but treatment decisions still require individual assessment of risks, benefits, access, and approved options. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).